Lymphoma
Conditions
Keywords
lymphoma, CLAP, China, patient registry
Brief summary
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With the progress of treatment, the survival rate of lymphoma patients has been improved. But the 5 year survival rate of lymphoma in China is shorter than that in United States. The reason is that there is still a gap between China and the United States in disease screening, diagnosis and treatment. Observational studies, especially cohort studies, are important tools for understanding disease progression, treatment, and prognosis in the real world. Observational cohort studies which involve over 500 patients are currently launched by South Korea and the United States. China, which has more patients, doesn't have a cohort of patients with lymphoma. So the primary objective of this study was to establish an observational cohort of patients with lymphoma in China and follow up the patients for a long period of time to provide basic support for clinical research and drug development, and continuously improve patient outcomes and quality of life. The secondary objective is to collect information about diagnosis, treatment, follow-up and prognosis of lymphoma.
Detailed description
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With the progress of treatment, the survival rate of lymphoma patients has been improved. But the 5 year survival rate of lymphoma in China is shorter than that in United States. The reason is that there is still a gap between China and the United States in disease screening, diagnosis and treatment. Observational studies, especially cohort studies, are important tools for understanding disease progression, treatment, and prognosis in the real world. Observational cohort studies which involve over 500 patients are currently launched by South Korea and the United States. China, which has more patients, doesn't have a cohort of patients with lymphoma. So the primary objective of this study was to establish an observational cohort of patients with lymphoma in China and follow up the patients for a long period of time to provide basic support for clinical research and drug development, and continuously improve patient outcomes and quality of life. The secondary objective is to collect information about diagnosis, treatment, follow-up and prognosis of lymphoma.
Interventions
None listed
Sponsors
Peking University First Hospital
Tianjin Medical University Cancer Hospital
Zhejiang Cancer Hospital
Heilongjiang Cancer Hospital
Sipai(Beijing)Network Technology Co Ltd
Jun Zhu
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma * 18 years of age or older at diagnosis * The diagnosis was confirmed within 6 months before admission * Informed consent was obtained
Exclusion criteria
* There are no special
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characteristics of lymphoma in China， | 5 years | Understand the characteristics of lymphoma in China,such as the distribution of sex,age,histological type and clinical stage etc |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 10 years | Overall survival is defined as the time from disease to death |
Countries
China
Contacts
Primary ContactYuqin Song, Ph D
Outcome results
None listed